Blood thinners and supplements before a cosmetic procedure: build one medication handoff

A cosmetic clinic’s blanket “stop blood thinners and supplements” sheet is not a safe medication plan. Anticoagulants and antiplatelet drugs may prevent stroke, clot, or device-related events; stopping them can carry risk, while continuing them can change bleeding or bruising. The prescribing clinician and procedural team must reconcile the exact medicine or supplement, reason for use, dose, last dose, kidney or liver context when relevant, procedure and anesthesia, planned change if any, and restart owner. Do not change a prescribed product from this article or an intake checklist.¹²³

The procedure may be a small injection, a vascular laser, a peel, a biopsy, or major surgery. Those do not share one bleeding profile, so they should not share one automatic instruction.

“Blood thinner” contains several mechanisms

The American College of Surgeons recommends disclosing prescriptions, vitamins, minerals, herbs, drugs, and supplements and asking about both clot and bleeding risk.¹ A category is a prompt for reconciliation, not a universal stop interval.

Start with why the product exists

Record the indication: atrial fibrillation, prior clot, stroke prevention, coronary stent, vascular disease, pain, inflammation, supplement use, or another reason. The same drug name can carry very different interruption consequences depending on why it was prescribed and how recently the underlying event or procedure occurred.

Ask:

• Who prescribed or recommended it?
• What condition or device does it address?
• Is the dose scheduled, as-needed, or recently changed?
• Has the person had bleeding, clotting, kidney, liver, or platelet issues?
• Is another clinician managing monitoring?
• Has a prior procedure required an interruption or bridge?

Do not infer that a medicine is optional because the person feels well. MedlinePlus specifically warns not to stop warfarin without the treating clinician.³

Name the cosmetic procedure at operational depth

“Facial treatment” is not enough. Document:

• needle, cannula, incision, energy, peel, or other mechanism;
• body site and vascularity;
• number and size of punctures or incisions;
• expected tissue depth;
• local, sedation, or general anesthesia;
• whether compression or direct hemostasis is possible;
• implanted product or device;
• duration and combined procedures; and
• response plan for bleeding or hematoma.

A small bruise around a superficial injection and an expanding postoperative hematoma are different events. The proceduralist must classify the actual plan.

Supplements need ingredient-level reconciliation

“Multivitamin,” “greens,” “sleep support,” and “hair vitamins” can contain multiple active ingredients. Photograph every label panel and record brand, lot when available, serving size, actual use, and last dose. Include teas, powders, drops, gummies, injections, IV ingredients, nicotine, alcohol, cannabis, and CBD when the anesthesia or procedure team asks.

Do not rely on a memorized list of “blood-thinning herbs.” Formulation, dose, evidence, and product quality vary. The clinician’s job is to evaluate the exact exposure and procedure, not to declare all natural products safe or dangerous.

The prescriber and proceduralist need one closed loop

A defensible handoff has both sides:

1. proceduralist states exact procedure, date, bleeding consequences, anesthesia, and preferred medication conditions;
2. prescriber states the indication and risk of a change;
3. anesthesia professional adds procedure-specific requirements when involved;
4. one clinician writes the final product-by-product instruction;
5. patient receives dose and date language;
6. team confirms what was actually taken; and
7. restart responsibility and warning response are assigned.

“Cleared by cardiology” is incomplete without the dated instruction and exact procedure.

A cosmetic cancellation policy should accommodate clinical changes

Medication review can change the date or scope. Read deposit, cancellation, rescheduling, product-opening, and travel terms before paying. Ask whether a safety-driven delay preserves the deposit and whether a changed procedure requires a new estimate and consent.

This matters when the clinic requests an interruption only after the nonrefundable period. Commercial pressure should not decide the medication plan.

Bruising prevention and medical safety are not the same objective

A clinic may recommend stopping a product mainly to reduce visible bruising. The prescriber may prioritize preventing a serious clot. Both outcomes belong in the conversation, but cosmetic bruising cannot silently outrank the indication for prescribed therapy.

Ask the proceduralist which outcome the instruction addresses:

• ordinary bruising;
• prolonged puncture bleeding;
• surgical blood loss;
• hematoma;
• anesthesia;
• interaction with another drug; or
• inability to manage a complication in the setting.

Then confirm that the person responsible for the medication understands that reason.

Day-of-procedure verification closes the gap

Bring the current list and products when requested. The team should confirm actual last doses, new medicines, illness, alcohol or cannabis exposure when relevant, and any instruction conflicts. If the list does not match the written plan, pause the workflow until the responsible clinician resolves it.

Keep the final medication reconciliation, procedure record, product or device details, and aftercare contact. The office-surgery guide shows how facility and response capability add another safety layer for surgical care.

Build the handoff instead of following a list

1. Inventory every exposure. Record prescription, OTC, vitamin, herb, supplement, injection, infusion, nicotine, alcohol, cannabis, and CBD products by active ingredient and actual use.
2. Name each indication. Identify why the product exists, who prescribed it, recent clot or bleeding history, devices, and monitoring.
3. Define the procedure. Specify mechanism, body site, depth, punctures or incisions, anesthesia, combined work, and consequences of bleeding.
4. Connect responsible clinicians. Have proceduralist, prescriber, and anesthesia professional exchange the exact procedure and product information.
5. Write product-by-product instructions. Record continue or change decision, dates, dose details, confirmation checks, restart owner, and what remains unresolved.
6. Reconcile on the day. Confirm what was actually taken, resolve conflicts before treatment, and preserve the final list and response pathway.

The decisive question is: “Which named clinician balanced the clot and bleeding consequences of this exact product for this exact procedure—and where are the last-dose, restart, and response instructions written?”